IRD - opusgtx.com Profit before interest, taxes and amortization

Graphic logo of Opus Genetics, Inc. (IRD)

Opus Genetics Inc (IRD) is developing advanced gene therapy methods to combat rare retinal pathologies. Partnerships with scientific foundations are helping to accelerate the release of innovative ophthalmological drops. However, the lack of profitable products leaves the company dependent on external financing, and the absolute EBITDA trend confirms this status, where the value 0.00 captures the current operating profit figure.

Profit before payment of interest, taxes and amortization: Opus Genetics (IRD) for 11/23/2025 - 11/10/2026

Opus Genetics - analytical breakdowns and key metrics (IRD)

- market value and analyst target forecast:
Market Price Opus Genetics, Inc.|IRD - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Opus Genetics|IRD - Total Company Value
- book capitalization data:
Net Assets per Share Opus Genetics|IRD - Company Book Value|Market-to-Book Ratio opusgtx.com|IRD - Aggregate Company Assets
- debt level and financial liquidity data:
Aggregate Debt to Equity Opus Genetics Inc|IRD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Opus Genetics, Inc.|IRD - Company Debts|Debts to Net Assets Opus Genetics|IRD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Opus Genetics|Critical Liquidity opusgtx.com
- company profitability and valuation multiples indicators:
IRD - Net Profit|Expected Net Profit Opus Genetics Inc|IRD - Price to Earnings Ratio|Price to Future Earnings Ratio Opus Genetics, Inc.|IRD - PEG Multiple|Company Value to EBITDA Opus Genetics|IRD - Operating profit before deduction of amortization|Earnings per share for the last four quarters Opus Genetics|IRD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months opusgtx.com|IRD - Earnings growth in current year|Expected earnings per share growth for next year Opus Genetics Inc
Analysis of all company metrics:IRD Opus Genetics Inc
Finished products of Opus Genetics

Absolute operating profit before interest and taxes measures a business's actual ability to generate cash flow from core operations, excluding the impact of debt load and fiscal policy. By analyzing the EBITDA trend, an investor assesses the commercialization efficiency of Opus Genetics Inc. (IRD), where financial results depend on clinical successes and patents rather than macroeconomic cycles.

Competitor analysis for Opus Genetics Inc

Alcon Corp (ALC) - Profit before interest, taxes and amortization|Bausch + Lomb Corporation - Operating profit EBITDA|Profit before interest, taxes and amortization glaukos.com|Apellis (APLS) - Profit before payment of interest, taxes and amortization|BLTE - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Ocular Therapeutix Corp|Profit before interest, taxes and amortization Harrow Corp HROW|Profit before payment of interest, taxes and amortization Viridian Therapeutics (VRDN)|LENZ: Profit before deduction of interest, taxes, depreciation and amortization|Oculis Holding - Operating profit before deduction of amortization|Operating profit EBITDA EyePoint Pharmaceuticals Inc EYPT|KOD - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Aldeyra Therapeutics ALDX|KALA (kalarx.com) - Operating profit before deduction of amortization|OKYO Pharma - Income before deduction of interest, taxes and amortization|ADVM (Adverum Biotechnologies Inc.) - Operating profit EBITDA|OTLK - Operating profit before depreciation charges|Operating profit EBITDA CLSD|NBY - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Kiora Pharmaceuticals, Inc. KPRX|ALIM: Operating profit before amortization|Eyenovia Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Guardion Health Sciences, Inc.|OCUP (Ocuphire) - Operating profit before deduction of amortization|OPT: Company profit before taxes, interest and amortization